LSX 2024 - Dr Tadaaki Taniguchi

At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some recent news.

They discuss new data Astellas recently presented on human trials of a first-in-class KRAS-targeted TPD treatment, using targeted protein degradation to drug previously undruggable targets.

Taniguchi also talks about the 400-person office in Cambridge, Massachusetts Astellas just opened and how it will help the company moving forward, and gets into their existing presence in Massachusetts coming out of the 2015 Ocata acquisiton and the 2017 acquisition of Mitobridge.

Finally, Taniguchi speaks briefly about what’s coming up next for Astellas. Check out the full video below.